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vaccine prevents 408 469 cases of precancerous cervical lesions. Due to HPV vacci-
nation the incidence of CC is reduced by1858 cases, which corresponds to 31 588
years of life saved in the vaccinated cohort. The cost of an additional life-year saved
is 10,166 € (405,535 rubles), and the cost of averted CIN case is 786 € (31,360 rubles).
CONCLUSIONS: Vaccination with Human Papillomavirus recombinant vaccine
seems a cost-effective option in Russia.
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OBJECTIVES: Pertussis incidence has been increasing in adolescents and adults in
the last two decades with transmission to vulnerable young infants. This epidemi-
ological changing has raised interest in the cost-effectiveness of booster vaccina-
tion (extra administration of a vaccine after an earlier dose). A critical review of
economic evaluations of pertussis booster vaccination was performed in order to
develop recommendations for future studies. This review illustrates specific chal-
lenges encountered in economic evaluations of vaccination programmes.
METHODS: The literature search covered cost-effectiveness studies of pertussis
booster vaccination, published until November 2010, worldwide. We extracted in-
formation on model structures, input data and results. RESULTS: We identified 13
publications (9 distinct models) referring to cost-effectiveness of pertussis booster
vaccination. The most frequently studied strategies were adolescent booster vac-
cination (9/13), cocooning strategy, i.e. vaccination of mothers and family mem-
ber(s) of newborn infants (6/13), one-time adult pertussis booster vaccination (6/
13), and decennial vaccination of adults with pertussis containing boosters (4/13).
All studies found that booster vaccination was a cost-effective or cost-saving strat-
egy compared to no booster vaccination. However, conclusions differed concerning
the exact age groups to vaccinate and frequency of vaccination. Results were
strongly affected by assumptions regarding unreported cases and uncertainty
around incidence. Four models ignored herd immunity (HI) effects, 3 assumed
incidence reduction attributable to HI, and 2 were transmission dynamic models
predicting HI effects. Several studies considered incidence at steady state, al-
though it was not reached before 80 years for some strategies. Methods used to
compare multiple strategies were often inappropriate. CONCLUSIONS: Reviewed
studies showed that pertussis booster vaccination is cost-effective or dominant vs.
no booster vaccination, but did not identify any optimal vaccination schedule.
Results are variable due to uncertainty surrounding disease incidence and extent
of HI. Future economic evaluations should explore a wider range of strategies,
according to local context.
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OBJECTIVES: Rotavirus infection causes severe gastroenteritis in children world-
wide. Its disease burden has been reduced in countries where mass rotavirus vac-
cination programmes have been introduced. England and Wales (E&W) have not
yet implemented such a mass vaccination programme, but are currently re-evalu-
ating its potential cost-effectiveness. Our study uses a dynamic model to predict
the epidemiological and economical effect of such a mass vaccination programme
in E&W beginning in the autumn of 2011. METHODS: A previously published age-
structured dynamic model was upgraded and parameterised with country-specific
data for the introduction of the oral rotavirus pentavalent vaccine. We report the
impact of vaccination on disease incidence reduction, timing of seasonal epidem-
ics and herd immunity levels. The model was then used to assess whether a mass
vaccination of RotaTeq is cost-effective and affordable for E&W. RESULTS: Our
results predict that vaccination can reduce the burden of severe disease by 70% and
delay the epidemic peak by two and a half months with coverage of 95%. Our
calculations further show that herd immunity accounts for about a quarter of the
reduction in incidence. If the pentavalent vaccine-induced immunity does not
wane over five years, severe disease in children under five years of age is elimi-
nated within two years after the introduction of vaccination. The probability of a
mass vaccination strategy being cost-effective is presented under likely vaccine
waning scenarios, administration cost assumptions and possible dose prices.
CONCLUSIONS: This work allows policymakers to determine both the epidemio-
logical impact and cost implications of a mass vaccination programme against
rotavirus with the pentavalent vaccine in England and Wales. Although long con-
sidered unlikely to be cost-effective in E&W using static models, the pentavalent
vaccine demonstrates a significant impact in reducing rotavirus cases at accept-
able levels of cost-effectiveness when using appropriate modelling techniques.
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OBJECTIVES: Evaluation of comparative cost-effectiveness of CAP treatment with
moxifloxacin versus combined therapy with cefotaxime and macrolides in adult
patients.METHODS: Patients were randomized in two groups. MOX group received
moxifloxacin 400 mg i.v. once-daily with further switch to oral formulation 400 mg
daily. COMB group received either cefotaxime 1000 mg i.m. 3 times per day as
monotherapy or in combination with oral azithromycin or clarithromycin. Efficacy
and safety criteria were evaluated according to clinical data, laboratory tests and
X-ray examination. Cost-effectiveness analysis was performed. RESULTS: MOX
group included 30 patients, mean age 33.616.5 years; COMB group included 50
patients, mean age 26.515.6 years. The efficacy of moxifloxacin treatment was
96.7%, in-hospital stay duration was 15.93.3 days. The efficacy of treatment in
COMB group was 88.0%, patients were discharged after 18.23.7 days. Direct med-
ical costs including antibacterial treatment and in-hospital days were 46712 RUB
(€1173) in MOX group and 46970 RUB (€1180) in COMB group. CERMOX 48307 RUB
(€1213), CERCOMB 53375 RUB (€1340). CONCLUSIONS: CAP treatment with moxi-
floxacin compared to combined therapy with cefotaxime and macrolides in adult
patients is more effective and cost saving technology.
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OBJECTIVES:To assess the cost-effectiveness of universal rotavirus immunization,
explicitly the use of Rotateq® and affordability of implementing rotavirus immu-
nization based on the Global Alliance for Vaccines and Immunization (GAVI)-sub-
sidized vaccine price in the context of Vietnamese health care system for the next
5 years. METHODS: An age-structured cohort model was developed for the 2009
Vietnamese birth cohort and applied a 5-year time horizon with time cycle of 1
month for 1-year-old children and annually thereafter. Results from no vaccina-
tion and vaccination were compared. Outcomes included rotavirus episodes re-
quiring home-treatment, outpatient visits, hospitalizations and deaths. Multiple
outcomes per rotavirus infection are possible in the model. Acceptability and af-
fordability analyses were done using Monte Carlo simulations. Costs were ex-
pressed in 2009 US$. RESULTS: Rotavirus immunization would not completely
protect under-five-year-old children against rotavirus infection due to partial na-
ture of vaccine immunity, however, would effectively reduce rotavirus severe cases
by 55%. Under the GAVI-subsidized price, the minimum vaccination budget
would be US$1.6 million annually. In the base-case, the incremental cost per qual-
ity-adjusted-life-year (QALY) was US$665 from health care perspective,Vietnam-
ese per-capita-GDP in 2009. Affordability results showed that at the GAVI-subsi-
dized vaccine price, rotavirus vaccination could be affordable in Vietnam.
CONCLUSIONS: Rotavirus immunization in Vietnam would be a cost-effective
health intervention. However, it only becomes affordable under the GAVI’s finan-
cial support. Vaccine price is the most crucial factor to decision-makers regarding
introducing this vaccine into the country’s immunization. Given the high under-
five mortality rate, results showed that rotavirus immunization is the “best hope”
for prevention of rotavirus-related diarrhoeal disease in Vietnam. In the next five
years, Vietnam is definitely in debt to external financial support in implementing
rotavirus vaccination. It is recommended that new and cheaper rotavirus vaccine
candidates be developed to speed up rotavirus vaccines introduction in the devel-
oping world.
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OBJECTIVES: To estimate the cost and effects of initiating treatment with atazana-
vir/r (ATV/r) compared to darunavir/r (DRV/r), lopinavir/r (LPV/r) and efavirenz
(EFV) in treatment-naïve HIV-1 patients in Italy(I), Spain(S), Portugal(P) and UK.
METHODS: HIV-disease progression is modeled using a micro-simulation model.
Health states are a function of HIV-RNA, CD4cells, AIDS defining events (ADEs),
and comorbidities. At model entry patients receive either ATV/r, LPV/r, DRV/r, or
EFV with a treatment backbone. Treatment-sequences are modelled following
treatment discontinuation due to virological failure, adverse events, resistance, or
treatment related co-morbidities. Country-specific patterns for HIV related drug
use were applied to estimate specific treatment sequences; maximized at 8 treat-
ment lines after which patient were assumed to be untreated. Efficacy and tolera-
bility inputs of first line treatments were derived from a Mixed-Treatment-Com-
parison, supplemented by published literature and product-SPCs for remaining
drug specific data for efficacy, tolerability and safety. Occurrence of (non)-AIDS
defining malignancies was linked to current CD4cell count and independent of
therapy. Cost estimates were based on country specific sources. A 25-year time-
horizon was chosen for the base-case analyses. A payer’s perspective was chosen
and country-specific discount rates were applied. RESULTS:Across countries, total
costs per patient who started with ATV/r ranged between €126,947(I) and
€154,285(P). Predicted incremental costs of ATV/r versus comparators ranged be-
tween -€27,004 (S) versus LPV/r and -€13,165 (P) versus EFV. Estimated incremental
QALYs of ATV/r versus comparators varied from -0.68(UK) versus EFV to 0.78(UK)
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